Caris Life Sciences, Inc. · NASDAQ:CAI
Caris Life Sciences — Q2 2026 Earnings Presentation
21 slides from Caris Life Sciences's earnings presentation, Aug 5, 2026
Slide 1: Where Molecular Science Meets Artificial Intelligence
Where Molecular Science Meets Artificial Intelligence Q2 2026 Earnings Call August 5, 2026
Slide 2: Important Information and Disclaimer
Important Information and Disclaimer Forward-Looking Statements Non-GAAP Financial Measures This presentation contains forward-looking statements, within the meaning of the Private Securities Litigation We use certain financial measures not calculated in accordance with generally accepted Reform Act
Slide 3: Differentiated technology across the cancer journey
POWERFUL MOLECULAR PLATFORM Differentiated technology across the cancer journey WES / WTS / IHC WES / WTS / CH WGS / WTS Tissue-based therapy selection Blood-based therapy selection Heme therapy selection COMMERCIAL COMMERCIAL COMMERCIAL Digital AI WGS/WTS WES / WTS / WGS Early-stage breast predicto
Slide 4: Strong Revenue and Clinical Volume Growth
Strong Revenue and Clinical Volume Growth Q2 Revenue Q2 Clinical Case Volume ($ in millions) +18% YoY +45% YoY Pharma R&D Services Molecular Profiling Services $263.7 $11.4 59,200 $181.4 $18.5 50,000 $252.3 $162.9 Q2 2025 Q2 2026 Q2 2025 Q2 2026 ©2026 Caris Life Sciences 4
Slide 5: Q2 2026 Performance Highlights
Q2 2026 Performance Highlights FINANCIAL PERFORMANCE ADDITIONAL OPERATING HIGHLIGHTS Launched Caris Detect TOTAL REVENUE MOLECULAR PROFILING REV A groundbreaking multi-cancer early detection blood test. $263.7M +45% YoY $252.3M +55% YoY Salesforce Expansion 290 team members as of June 30, 2026. CLIN
Slide 6: Commercial Execution Driving Sequential Acceleration from Q126
Commercial Execution Driving Sequential Acceleration from Q126 CLINICAL CASE VOLUME ADDITIONAL COMMERCIAL HIGHLIGHTS +18% YoY 48,300 MI Profile cases 13% YoY · 11% sequential growth ▲ 12% 10,700 Caris Assure cases Sequentially 50% YoY · 17% sequential growth +6,400 Cases 59,200 290 commercial team m
Slide 7: Redefining Early-Stage Cancer Detection
Redefining Early-Stage Cancer Detection
Slide 8: Caris Detect: Tumor Type Update
Caris Detect: Tumor Type Update 58 Cancer Types Detected Coverage spans solid tumors, hematologic malignancies, and unresolved cancer-signal localization from a routine blood draw. LUNG / THORACIC UPPER GI PRIMARY BRAIN TUMOR SOFT TISSUE TUMORS - Non-small cell lung cancer - Esophageal carcinoma - G
Slide 9: Caris Detect: Tissue-of-Origin Classifier
Caris Detect: Tissue-of-Origin Classifier Pinpointing the tumor's origin, early — with fewer procedures The classifier concentrates probability on the true site, turning an open-ended cancer hunt into a short, prioritized workup. NARROWING THE SEARCH BY THE NUMBERS Lung Cervical CRC Melanoma Breast
Slide 10: Caris Detect: Tissue-of-Origin Classifier
Caris Detect: Tissue-of-Origin Classifier Every result is delivered as a prioritized workup — per-site probabilities paired with the exact screening study to order. THE DELIVERABLE WHAT THE REPORT COMMUNICATES A clear, actionable result 1 “Cancer Signal Detected” is stated plainly, backed by whole-g
Slide 11: Mutational Cleanse: From Personalized Medicine to Personalized Prevention
Mutational Cleanse From Personalized Medicine To Personalized Prevention
Slide 12: Early detection to personalized immune interception
MUTATIONAL CLEANSE Early detection to personalized immune interception • First Caris Detect identifies disease early • Caris MAX 10,000x whole-exome sequencing to identify somatic neoepitopes • Use our proprietary AI to identify immunogenic mutations for personalized immunotherapy. Caris AI Performa
Slide 13: Pipeline Update
Pipeline Update MI Clarity • Caris MRD Clinical Evidence
Slide 14: Caris MI Clarity: Upgraded
Caris MI Clarity: Upgraded Upcoming Version 2 brings treatment decision support to patients who were not tested at diagnosis V1 Capabilities NEW V2 Both early & late recurrence prognosis Chemotherapy decision support ✓ Distant-recurrence risk across Years 0–5 and Years 5–15 ✓ Identifies eligible pre
Slide 15: Caris MRD Update
Caris MRD Update Two complementary approaches to minimal residual disease TUMOR NAIVE TUMOR INFORMED WHOLE EXOME WHOLE GENOME WHOLE TRANSCRIPTOME Intended use: Pan-tumor, Stage I–III. Tumor / normal WGS identifies trackers; a comprehensive approach minimizes false negatives and maximizes tracker cou
Slide 16: The Comprehensive Advantage
CLINICAL EVIDENCE The Comprehensive Advantage Caris testing reveals what targeted gene panels miss — in both therapy eligibility and treatment outcomes. STUDY 1 STUDY 2 Caris Lookback Program: comprehensive Whole-exome TMB drives better outcomes than testing keeps delivering value targeted gene pane
Slide 17: Financial Update
Financial Update Financial Overview 2026 Guidance Update
Slide 18: Q2 2026 Financial Overview
Q2 2026 Financial Overview Selected financial metrics All amounts millions except gross margin TOTAL REVENUE GROSS MARGIN(1) $263.7M 68% Q2 2025 Q2 2026 Change +45% vs. Q2 2025 +500 bps vs. Q2 2025 GAAP Total Revenue $181.4M $263.7M +45% ADJUSTED EBITDA(2) FREE CASH FLOW(2) Molecular Profiling Reven
Slide 19: Molecular Profiling Growth Driven by Volume and ASP
Molecular Profiling Growth Driven by Volume and ASP Molecular Profiling Services Revenue ADDITIONAL HIGHLIGHTS ($ in millions) +55% YoY Total Blended base ASP Revenue Base Accrual Revenue from prior period performance obligations Surpassed $3,850 252.3 75% MI Cancer Seek 23.6 Stable Tissue volume mi
Slide 20: Raising full year guidance on strong Q2 performance
Raising full year guidance on strong Q2 performance Total Revenue $1.03BN – $1.04BN Up from $1.00–$1.02BN on profiling strength. 27% – 28% YoY Broad-based demand across the portfolio and continued Clinical Therapy Selection Volume ~20% YoY commercial expansion. GAAP Operating Expenses $595M – $600M
Slide 21: Slide 21